Objective: To assess patient and medication factors that contribute to metronidazole toxicity.
M
etronidazole is a 5-nitroimidazole antibiotic with potent activity against anaerobic bacteria and protozoa. The range of its use is broad and includes trichomonal infection, amebiasis, management of Crohn disease, hepatic encephalopathy, treatment of Helicobacter pylori infection and Clostridium difficileY associated diarrhea. While metronidazole is fairly safe and well tolerated, it can rarely cause serious neurological adverse events, including peripheral neuropathy, 1Y6 cerebellar dysfunction, encephalopathy, ototoxicity, 7 seizures, visual impairment, 8Y10 and altered mental status. It has been suggested that neurological toxicity may be related to prolonged administration, high doses, or high cumulative doses of metronidazole. 11Y14 We recently had an illustrative case: an 83-year-old woman with a surgical history of choledochojejunostomy for common bile duct stone 35 years ago who was transferred to our emergency department in shock and found to have a multilobular liver abscess. She was discharged on cefoprazone but presented a month later with recurrent liver abscess. She was subsequently discharged on ciprofloxacin (250 mg 2 times a day) and metronidazole (500 mg 3 times a day). After 2 days, she began to experience difficulty in speaking and dysarthria. Over the next couple of weeks, she developed an unsteady gait and bilateral lower extremity paresthesia and by day 14, she was unable to stand or walk. A magnetic resonance image (MRI) demonstrated lesions in the splenium of corpus callosum ( Fig. 1 ), felt to be metronidazole-induced cerebellar toxicity, and metronidazole was discontinued. She experienced gradual but complete resolution of symptoms by day 20 and a followup MRI of the brain 28 days after discharge revealed complete resolution of the previous abnormalities (Fig. 2) .
Our review of the literature revealed several case reports but no distillation of the literature and uncertainty about the role of dose or duration and the course and outcome of metronidazole toxicity. The purpose of this study was to perform a systematic review to synthesize the literature on this unusual adverse event.
MATERIALS AND METHODS

Data Sources and Searches
We searched PUBMED using several search strategies: ( 
Study Selection
We included all articles that reported cases of metronidazoleinduced central nervous system toxicity. We excluded nonEnglish or Japanese articles and those focusing on peripheral neuropathy. occurred and length of time after cessation of metronidazole for symptoms to resolve. Finally, we abstracted information reported regarding MRI findings.
Data Synthesis and Analysis
Our process yielded patient-level data. We provided descriptive statistics (means, medians, and proportions) for all data abstracted. We compared continuous variables between different groups using either analysis of variance or the Kruskal-Wallis test, depending on the underlying distribution. Categorical variables were compared using the W 2 test.
RESULTS
The literature search yielded 261 unique articles. Hand review of the bibliographies of these yielded 5 additional articles. Review of these 266 articles yielded 46 English and Japanese articles that reported 64 cases of metronidazole-induced central nervous system toxicity (Table 1) 37, 47 Canada, 44 and the United Kingdom, 27, 51 and single cases were from Belgium, 8 Chile, 25 Germany, 46 Israel, 18 the Netherlands, 28 Nigeria, 41 Taiwan, 2,41 Tunisia, 30, 41 and Turkey. 16 The first case report appeared in 1977 26 ; 37 (59%) of the reports have occurred since 2004. The mean age of affected patients was 53.4 years (95% confidence interval [CI]: 48.8Y57.9). The patients ranged in age from 12 to 87 years, with the peak occurring in the fifth and sixth decades. Forty-one (64%) of the patients were male. The most common indication for metronidazole treatment was abscess (n = 29 [48%]), followed by inflammatory bowel disease (n = 7 [12%]), C. difficile (n = 5 [8%]), and cellulitis (n = 4 [7%]). The mean duration of metronidazole treatment was 54 days (95% CI, 21.2Y87.9), although 26% of the patients had taken the drug for less than a week and 11% had taken it for less than 3 days. The average daily dose was 719 mg (range, 250Y2000 mg), and the average cumulative dose of metronidazole was 93.4 g (range, 0.25Y1095 g).
Types of Metronidazole-Induced Central Nervous System Toxicity
Of the 64 patients, 48 (75%) had cerebellar dysfunction, 21 (33%) had altered mental status, and 8 (13%) had seizures; 11 (17%) patients had both cerebellar dysfunction and altered mental status. One case each had cerebellar dysfunction and seizures; one had all 3 manifestations. Among the 48 patients with cerebellar dysfunction, dysarthria (n = 32 [66%]) and ataxia (n = 27 [56%]) were common; 16 (33%) had dysmetria and 4 (8%) nystagmus.
Among the patients with cerebellar dysfunction, 34 (71%) were male. The average age was 53 years, and the patients had been on metronidazole for a median of 30 days (range, 2Y730 days). The patients with acute mental status changes were younger, 43 years of age, and 13 (65%) were male. The median duration of treatment was 15 days (range, 1Y90 days). 
Brain Imaging Findings
Nearly all patients (n = 55 [86%]) underwent brain imaging: 44 (69%) underwent MRI examinations, and 12 (19%) underwent computed tomographic studies (one underwent both). Subjects with cerebellar dysfunction commonly had an MRI (n = 42 [88%]) while patients presenting with seizures underwent computed tomographic examinations (n = 6 [67%]).
All but one patient with cerebellar dysfunction who underwent imaging had an abnormality. Nearly all had cerebellar lesions (n = 39 [93%]), with the cerebellar dentate nuclei involved in most patients (n = 34 [81%]; Table 2 ). The corpus callosum, midbrain, pons, or medulla were involved in 26% to 40% of the patients with cerebellar dysfunction (Table 2) . Among the 9 patients with altered mental status, most had cerebellar dentate lesions (89%). Of these 9 patients, only 2 had altered mental status as their only neurological manifestation, and both had lesions in the cerebellar dentate nuclei and subcortical white matter.
Among the 44 patients who underwent brain MRI, 30 patients had a second brain MRI, performed 3 days to 3 months after cessation of metronidazole. Twenty-five (83%) had resolution of MRI abnormalities. Five patients had incomplete resolution of lesions or new changes. 28, 29, 31, 41, 43 There was poor correlation between symptom outcome and MRIs. The MRI abnormalities resolved even when the symptoms persisted, and improvement of symptoms preceded or followed changes in MRI findings.
DISCUSSION
Metronidazole-induced central nervous system toxicity is a serious but uncommon event. In this case series, metronidazole toxicity occurred in both men and women and in adults of any age. Although previous literature has suggested that toxicity is more common with higher doses or longer duration of therapy, we found that it occurs even with low doses or short exposure durations. There are 3 common patterns of toxicity: cerebellar dysfunction, mental status changes, and seizures. A smaller proportion of patients had more than one manifestation. Abnormalities in MRI are common, with cerebellar dentate lesions present in most images. The prognosis with cessation of metronidazole is good, with most of the patients improving or experiencing complete resolution of symptoms. Whereas most MRI findings will improve or resolve over time, there is only poor correlation between MRI resolution and symptom outcomes. A second MRI imaging is not required for patients who experience improvement in their symptoms.
The mechanism of metronidazole-induced central nervous system toxicity is uncertain. Proposed causes include binding of metronidazole to neural RNA to inhibit protein synthesis, modulation of inhibitory neurotransmitters F-aminobutyric acid receptor within the cerebellar and vestibular, reversible mitochondrial dysfunction, and vasogenic and cytotoxic edema. Previous case reports have demonstrated evidence of vasogenic or cytotoxic edema on MRI, suggesting either as a potential mechanism of neurotoxicity. At least one case report suggests having found evidence of both vasogenic and cytotoxic edema occurring in different parts of the brain.
Primary treatment of metronidazole-induced central nervous system toxicity is drug cessation and supportive care. Diazepam was found to reduce the time to recover the debilitating signs of dogs with metronidazole toxicosis compared with supportive care alone. However, there are no reports on using diazepam in treating metronidazole-induced central nervous system toxicity in human beings.
CONCLUSIONS
Metronidazole-induced central nervous system toxicity is uncommon but can present as cerebellar dysfunction, altered mental status, or seizures. There does not seem to be an association between duration or dose of metronidazole and toxicity; small amounts of metronidazole can induce neurotoxicity. The underlying pathophysiology is uncertain, although some have argued for cytotoxic or vasogenic edema. Treatment is cessation of metronidazole and supportive care. Although prognosis is generally good, some subjects wind up with permanent disability. When T2-weighted fluid attenuated inversion recovery MRIs of the brain are obtained, abnormalities are commonVpresent in 93% of subjects; cerebellar dentate nuclei lesions are the most frequent abnormality seen. Repeated MRIs generally show improvement or complete resolution of abnormalities. 
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